Verrica Pharmaceuticals
VRCA
47 hedge funds and large institutions have $69.1M invested in Verrica Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 23 reducing their positions, and 5 closing their positions.
0.05% more ownership
Funds ownership: 3.41% → 3.46% (+0.05%)
2% less funds holding
Funds holding: 48 → 47 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
29% less capital invested
Capital invested by funds: $97M → $69.1M (-$27.8M)
65% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.97M |
| 2 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$1.5M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$566K |
| 4 |
DMK
David M. Knott
|
+$255K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$110K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.2M |
| 2 |
Los Angeles Capital Management
Los Angeles,
California
|
-$389K |
| 3 |
BlackRock
New York
|
-$273K |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$222K |
| 5 |
CIAS
Capital Investment Advisory Services
Raleigh,
North Carolina
|
-$172K |
VRCA Hedge Fund Activity: Q3 2020 in Review
47 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q3 2020, worth a combined $69.1M — down 29% from $97M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of VRCA and 4 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 8 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.97M. The largest seller was Fidelity Investments, cutting an estimated $3.2M.
- 47 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q3 2020, down from 48 in Q2 2020.
- Funds reported $69.1M of Verrica Pharmaceuticals stock for Q3 2020, down 29% quarter-over-quarter.
- 4 funds opened new Verrica Pharmaceuticals positions in Q3 2020 and 5 closed out, a net change of -1 holder.
- The largest Verrica Pharmaceuticals buyer in Q3 2020 was Millennium Management, an estimated $2.97M added.
- The largest Verrica Pharmaceuticals seller in Q3 2020 was Fidelity Investments, an estimated $3.2M sold.
Based on aggregated 13F filings for Q3 2020.